ArticleSaudi medical journal2024
Elevated levels of CD56+ T Cells, CD16+ CD56+ T Cells, and CD56dim NK Cells in herpes simplex virus type 1 seropositive healthy individuals.
Article in Saudi medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NK Cells: A Powerful Squad Versus SARS-CoV-2.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the numbers of natural killer (NK) cells, CD56+ T-cells and CD56- T cells, and the levels ofCD16 in healthy individuals seropositive for herpes simplex virus Type 1 (HSV-1). Specifically, it seeks to measure the levels of these cells to learn about the possible immunological significance during HSV-1 seropositive status.
methodsThis study employed a cross-sectional research design to examine the levels of CD56+ T-cells and CD16+ among individuals seropositive for herpes simplex virus type 1 (HSV-1) in Taif city. A total of 112 participants were enrolled, with HSV-1 serostatus determined via ELISA, and cellular evaluation conducted using flow cytometry. The study was performed between January 2023 to July 2023.
resultsOur study found 36% HSV-1 seropositivity, contrasting with higher rates in Saudi Arabia. No significant age or gender differences were observed. HSV-1 seropositive individuals showed elevated dim CD56 NK cells and CD56+ T-cells, aligning with prior research on lymphocyte infiltration during HSV-1 activation. Further investigation is warranted for CD56- T-cells and bright NK cells.
conclusionHSV-1 seropositive individuals showed elevated dim CD56 NK cells and CD56+ T-cells, consistent with lymphocyte activities during viral activation. CD16 expression on CD56+ T-cells suggests their involvement in viral defence, emphasizing the need for further investigation into immune responses against HSV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.